Saturday 17 October 2026
Export IART’s income statement to Excel — free account
Integra LifeSciences Holdings Corporation
IART Healthcare Medical Devices
Integra LifeSciences Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.6 billion, up 1.53% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 101.0%, free cash flow grew 193.5% and total debt rose 1.51%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
13.21
0.32
−2.37%
Follow IART
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 52.11 | 25.79 | 33.83 | 41.20 | 100.48 | 62.64 | 57.16 | 46.55 |
Piotroski F-Score |
5 | 5 | 4 | 8 | 7 | 6 | 6 | 5 | 3 | 8 |
P/S ratio |
0.58 | 1.08 | 2.25 | 2.97 | 3.68 | 4.01 | 3.29 | 2.54 | 3.03 | 3.19 |
Altman Z-Score |
0.62 | 1.22 | 2.05 | 2.52 | 2.72 | 2.57 | 2.50 | 2.24 | 1.70 | 3.15 |
P/FCF ratio |
0.00 | 69.96 | 47.39 | 19.82 | 21.46 | 32.60 | 30.82 | 30.54 | 50.53 | 45.65 |
Altman Z″-Score (non-manufacturers) |
1.17 | 1.72 | 3.08 | 3.48 | 3.21 | 3.04 | 2.42 | 2.52 | 1.80 | 3.08 |
Beneish M-Score |
(3.25) | (2.61) | (2.56) | (2.42) | (2.56) | (2.80) | (2.70) | (2.52) | (2.14) | (2.50) |
P/Operating CF |
80.59 | 34.42 | 58.96 | 54.18 | 81.90 | 68.47 | 55.96 | 87.54 | 312.08 | 485.24 |
P/B ratio |
0.91 | 1.13 | 2.18 | 2.56 | 3.37 | 3.63 | 3.52 | 2.72 | 3.75 | 3.77 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
1.53 | 2.01 | 3.06 | 3.61 | 4.36 | 4.77 | 4.05 | 3.35 | 4.40 | 3.76 |
EV/EBITDA |
0.00 | 18.54 | 19.55 | 15.45 | 20.74 | 22.20 | 29.49 | 21.64 | 38.27 | 19.60 |
EV/Operating CF |
49.74 | 25.06 | 33.69 | 21.27 | 21.51 | 32.11 | 26.58 | 24.71 | 45.60 | 32.08 |
EV/FCF |
(80.70) | 129.88 | 64.52 | 24.11 | 25.42 | 38.83 | 37.99 | 40.32 | 73.22 | 53.81 |
Quick Ratio |
1.19 | 0.59 | 1.85 | 2.24 | 2.19 | 1.73 | 1.43 | 1.54 | 1.22 | 2.02 |
Current Ratio |
2.54 | 1.17 | 3.45 | 3.62 | 3.39 | 3.09 | 2.59 | 2.95 | 2.36 | 4.01 |
Net Debt/EBITDA |
(4.62) | 8.55 | 4.88 | 2.75 | 3.23 | 3.56 | 5.57 | 5.33 | 12.21 | 2.95 |
Debt/Assets |
50.45% | 43.82% | 39.27% | 37.49% | 41.28% | 42.07% | 41.17% | 43.59% | 57.33% | 36.78% |
Debt/Equity |
1.74 | 1.14 | 0.94 | 0.81 | 0.93 | 1.00 | 0.96 | 0.98 | 1.91 | 0.79 |
Asset Turnover |
0.43 | 0.41 | 0.40 | 0.41 | 0.42 | 0.40 | 0.47 | 0.47 | 0.47 | 0.55 |
Operating CF/Net income |
(0.10) | (18.63) | 2.07 | 1.46 | 1.85 | 1.52 | 4.61 | 3.28 | 1.77 | 1.56 |
Capex/Depreciation |
(0.61) | (0.78) | (0.52) | (0.25) | (0.38) | (0.25) | (0.61) | (0.66) | (0.47) | (0.63) |
Interest Coverage |
(5.72) | 0.40 | 2.17 | 4.82 | 3.91 | 2.11 | 1.74 | 1.72 | 1.28 | 4.47 |
| (39.90%) | (0.44%) | 3.99% | 10.35% | 10.57% | 9.13% | 3.60% | 5.20% | 7.19% | 9.37% | |
| (13.52%) | (0.18%) | 1.77% | 4.71% | 4.57% | 3.87% | 1.57% | 1.92% | 2.58% | 4.16% | |
ROIC |
(11.87%) | 0.58% | 2.52% | 5.32% | 4.51% | 3.69% | 2.27% | 2.68% | 1.07% | 5.14% |
Return on Tangible Assets |
(44.99%) | (1.23%) | 6.21% | 15.67% | 15.02% | 11.92% | 5.81% | 7.48% | 8.72% | 12.55% |
Average Days of Receivables |
62.24 | 61.73 | 61.40 | 61.74 | 54.86 | 60.01 | 66.21 | 65.87 | 77.35 | 54.52 |
Research and Development Expense of Revenue |
6.05% | 7.16% | 6.76% | 6.50% | 6.03% | 5.64% | 5.24% | 5.30% | 5.34% | 5.86% |
Selling, General and Administrative Expense of Revenue |
42.79% | 44.52% | 42.60% | 39.57% | 41.33% | 43.34% | 45.31% | 46.91% | 52.52% | 45.93% |
Intangible Assets out of Total Assets |
0.49 | 0.57 | 0.56 | 0.56 | 0.57 | 0.53 | 0.60 | 0.65 | 0.65 | 0.59 |
Share Based Compensation of Revenue |
1.14% | 1.51% | 1.31% | 1.78% | 2.35% | 1.43% | 1.40% | 1.41% | 1.81% | 1.74% |
Graham Net Nets |
(1.47) | (0.81) | (0.33) | (0.20) | (0.17) | (0.16) | (0.21) | (0.26) | (0.40) | (0.15) |
Graham Number |
0.00 | 0.00 | 19.24 | 32.51 | 29.77 | 25.19 | 14.69 | 16.40 | 15.20 | 15.24 |
Earnings Yield |
(54.19%) | (0.40%) | 1.92% | 3.88% | 2.96% | 2.43% | 1.00% | 1.60% | 1.75% | 2.15% |
Free Cash Flow Yield |
(3.26%) | 1.43% | 2.11% | 5.05% | 4.66% | 3.07% | 3.24% | 3.27% | 1.98% | 2.19% |
Revenue per Share |
21.33 | 20.91 | 19.25 | 18.77 | 18.21 | 16.21 | 17.72 | 17.77 | 15.45 | 13.34 |
Operating CF per Share |
0.66 | 1.68 | 1.75 | 3.19 | 3.69 | 2.41 | 2.70 | 2.41 | 1.49 | 1.56 |
Capex per Share |
(1.25) | (1.49) | (0.83) | (0.38) | (0.57) | (0.42) | (0.81) | (0.93) | (0.56) | (0.63) |
Free Cash Flow per Share |
(0.59) | 0.19 | 0.91 | 2.81 | 3.12 | 1.99 | 1.89 | 1.48 | 0.93 | 0.93 |
Cash per Share |
3.44 | 3.55 | 3.86 | 5.50 | 6.06 | 5.55 | 2.32 | 1.68 | 2.27 | 1.37 |
Shareholders Equity per Share |
13.61 | 20.07 | 19.83 | 21.74 | 19.89 | 17.90 | 16.54 | 16.60 | 12.51 | 11.29 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
13.61 | 20.07 | 19.83 | 21.74 | 19.89 | 17.90 | 16.54 | 16.60 | 12.51 | 11.29 |
Free Cash Flow |
(45.25) | 15.01 | 73.09 | 233.27 | 264.41 | 168.60 | 161.93 | 122.36 | 71.33 | 69.39 |
Working Capital |
703.56 | 159.56 | 751.06 | 840.59 | 813.70 | 836.19 | 526.86 | 512.53 | 473.24 | 371.57 |
Capital Expenditures |
(95.64) | (114.37) | (66.86) | (31.20) | (48.02) | (35.23) | (69.50) | (77.32) | (43.21) | (47.01) |
Net Current Asset Value |
(1,398.99) | (1,410.46) | (1,136.07) | (923.86) | (943.86) | (863.07) | (1,028.34) | (957.01) | (1,426.80) | (473.12) |
EV/EBIT |
0.00 | 114.12 | 42.28 | 23.54 | 34.08 | 43.25 | 65.62 | 44.45 | 116.57 | 32.37 |
Capex to Sales |
0.06 | 0.07 | 0.04 | 0.02 | 0.03 | 0.03 | 0.05 | 0.05 | 0.04 | 0.05 |
Price to Operating Income |
0.00 | 61.48 | 31.06 | 19.35 | 28.77 | 36.30 | 53.23 | 33.67 | 80.44 | 27.47 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.35 | 0.36 | 0.38 | 0.40 | 0.41 | 0.50 | 0.34 | 0.39 | 0.34 | 0.34 |
Cash ROIC |
(1.45%) | 0.42% | 2.16% | 6.27% | 7.03% | 4.81% | 5.44% | 4.26% | 2.40% | 4.32% |
Accounts Receivable Turnover |
5.93 | 6.06 | 5.90 | 6.29 | 6.75 | 5.48 | 5.61 | 5.69 | 5.94 | 7.08 |
Accounts Payable Turnover |
9.02 | 8.33 | 6.76 | 7.17 | 10.27 | 6.21 | 5.97 | 6.72 | 7.08 | 10.94 |
Inventory Turnover |
1.74 | 1.78 | 1.84 | 1.83 | 1.91 | 1.66 | 1.89 | 1.98 | 1.70 | 1.63 |
Average Days of Payables |
43.48 | 41.34 | 51.30 | 63.45 | 37.76 | 38.27 | 73.10 | 48.57 | 78.75 | 30.38 |
Days of Inventory on Hand |
223.80 | 215.00 | 216.50 | 201.71 | 193.78 | 217.33 | 204.29 | 179.05 | 248.35 | 227.17 |
Average Receivables |
275.61 | 265.85 | 261.40 | 247.65 | 228.68 | 250.41 | 270.52 | 258.77 | 199.99 | 140.21 |
Average Payables |
89.11 | 87.41 | 97.21 | 81.97 | 58.22 | 83.85 | 94.57 | 85.01 | 61.51 | 31.91 |
Average Inventory |
460.91 | 409.35 | 357.10 | 320.98 | 313.75 | 313.09 | 298.20 | 288.34 | 256.80 | 214.35 |
Average Assets |
3,819.71 | 3,909.71 | 3,835.87 | 3,836.07 | 3,698.76 | 3,459.19 | 3,205.56 | 3,159.57 | 2,509.61 | 1,791.09 |
Average Common Equity |
1,294.37 | 1,566.58 | 1,696.14 | 1,744.60 | 1,599.84 | 1,465.80 | 1,396.27 | 1,169.05 | 900.99 | 795.55 |
Columns are period end dates